Navigation Links
Genaera Corporation Announces Third Quarter Financial Results
Date:11/9/2007

tements reflect management's current views and are based on certain expectations and assumptions. Such statements include, among others, statements regarding the preliminary results, clinical development plans and prospects for Genaera's programs including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM), or squalamine. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to: Genaera's history of operating losses since inception and its need for additional funds to operate its business; the costs, delays and uncertainties inherent in scientific research, drug development, clinical trials and the regulatory approval process; the risk that clinical trials for Genaera's product candidates, including trodusquemine (MSI-1436), the IL-9 antibody program, LOMUCIN(TM), or squalamine may be delayed or may not be successful; the risk that Genaera may not obtain regulatory approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and interpreting data, regulatory interpretations of clinical risk and benefit, or otherwise; Genaera's reliance on its collaborators, in connection with the development and commercialization of Genaera's product candidates; market acceptance of Genaera's products, if regulatory approval is achieved; competition; general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industry; and the other risks and uncertainties discussed in this announcement and in Genaera's filings with
'/>"/>
SOURCE Genaera Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Genaera Elects New Board Member and Announces Executive Appointments
2. Genaera to Present at Biotech 2007 and BIO InvestorForum
3. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
4. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
5. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
6. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
7. BioElectronics Corporation Announces Singapore and Malaysia Sales
8. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
9. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
10. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
11. Luminex Corporation to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015 A ... the NCATS rare-diseases portfolio " in Science ... new financing technique to reduce the risk associated ... and potentially unlock new levels of funding for ... product of a unique collaboration between scientists at ...
(Date:2/27/2015)... 2015 Immunovaccine Inc. (“Immunovaccine”) (TSX: ... today announced that the U.S. Food and Drug ... designation and Phase I clinical trials of the ... mutual co-development agreement signed with Gilead Life Sciences. ... for the DPX-Survivac. , “We have been in ...
(Date:2/27/2015)... , Feb. 27, 2015 Bionomics Limited ... the DisrupTOR-1 trial of BNC105 in patients with metastatic ... Orlando, Florida . The data will ... the City of Hope Comprehensive Cancer Center in ... The new data identifies Ferritin and IL-8 ...
(Date:2/27/2015)... 27, 2015 FamilyFarms Group is pleased ... of State Line Farms, received the 2015 Tomorrow’s Top ... under the age of 35, who has demonstrated excellence ... honor to win the Tomorrow's Top Producer Horizon Award. ... the Top Producer Award and learning from their experiences. ...
Breaking Biology Technology:New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2
... ANGELES, Dec. 13 Give the person on your ... the form of a Magical Mystical,Pen by world-renowned artist, ... series of Magical Mystical Tour,abstracts, currently exhibited in the ... House Gallery in St. James, NY, through,January 11, 2008., ...
... be presented at San Antonio Breast Cancer Symposium, ... world,leader in the rapidly evolving field of molecular ... demonstrated the,prognostic power of its MammaPrint(R) breast cancer ... nodes. The data show that,MammaPrint(R) can accurately identify ...
... Patients treated with drug-eluting,stents must take a combination ... least one year, and possibly longer, after stent,implantation. ... update published,online today in the journals of the ... of Cardiology (ACC), and,American Heart Association (AHA). To ...
Cached Biology Technology:Artistic Magical Mystical Tours 2MammaPrint(R) Breast Cancer Test Validated in Lymph Node-Positive Breast Cancer Patients 2MammaPrint(R) Breast Cancer Test Validated in Lymph Node-Positive Breast Cancer Patients 3PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents 2PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents 3PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents 4
(Date:2/24/2015)... , Feb. 24, 2015 This report analyzes the ... provides separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Middle ... Annual estimates and forecasts are provided for the period 2013 ... these markets. Market data and analytics are derived from primary ...
(Date:2/24/2015)... 2015 Research and Markets ( ... "Global 2D Gesture Recognition Market 2015-2019" ... analysts forecast the Global 2D Gesture Recognition market ... the period 2014-2019 The increased demand ... one of the major trends in the market. ...
(Date:2/19/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/kx9zp8/military ) ... Electro-Optical / Infrared Systems Market by Type, by ... to 2020" report to their offering. ... expected to reach $16.35 billion by 2020, to ... report segments the military electro-optical/infrared systems market on ...
Breaking Biology News(10 mins):World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3
... of Biological Sciences has placed another piece in the puzzle ... and eggs get the right number of chromosomes. The ... half its chromosomes from each parent sperm and eggs ... humans have 23 pairs of 46 chromosomes: so our sperm ...
... -- Marsh plants, far from being passive wallflowers, are "secret ... odds of survival, says a team of scientists from Duke ... Scientists have long believed that the distribution of plants ... grow at different elevations because that,s where conditions like soil ...
... 2013 Annual Meeting of the Southeastern Branch of ... held March 3-6, 2013 at the Hilton Baton ... Hundreds of entomologists from Alabama, Arkansas, Florida, Georgia, ... will meet to discuss citrus greening disease, invasive ...
Cached Biology News:Clues to chromosome crossovers 2Marsh plants actively engineer their landscape 2
Rat Aortic Smooth Muscle Cells (RAOSMC) (>500,000 cells)...
Rat Dermal Fibroblasts (RDF) (>500,000 cells)...
... The miVac DNA is an ideal ... ,A centrifugal concentrator capable of removing water ... sample formats including tubes, microplates, vials and ... "work-horse" concentrator for the busy lab. ,The ...
... Brownlee Precision Model 440 incorporates four channels ... a friendly easy-to-use instrument. Each channel consists ... 8-pole Bessel lowpass filter, a highpass filter, ... controls. A control knob sets the amplifier ...
Biology Products: